scholarly journals Pretreatment Glasgow prognostic score as a predictor of outcomes in nivolumab-treated patients with advanced gastric cancer

PLoS ONE ◽  
2021 ◽  
Vol 16 (2) ◽  
pp. e0247645
Author(s):  
Nagahiro Tokuyama ◽  
Naoki Takegawa ◽  
Michiko Nishikawa ◽  
Aya Sakai ◽  
Takuya Mimura ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Overall Survival ◽  
Advanced Gastric Cancer ◽  
Median Overall Survival ◽  
Prognostic Score ◽  
Glasgow Prognostic Score ◽  
Prognostic Scores ◽  
Cancer Center ◽  
Number Of Patients ◽  
The Glasgow Prognostic Score

In Japan, South Korea, and Taiwan, nivolumab might provide overall survival benefits for patients with advanced gastric cancer. However, it is effective only in a limited number of patients. The Glasgow prognostic score is an indicator of the systematic inflammatory response and nutritional status. This study aimed to investigate the ability of the Glasgow prognostic score and other markers to predict the outcomes of patients treated with nivolumab. We reviewed the medical records of patients treated for advanced gastric cancer and who received nivolumab between February 2015 and June 2019 at Hyogo Cancer Center. The patients were categorized into two groups according to their Glasgow prognostic scores. Overall, 53.3% and 46.7% of the patients were assigned to groups with Glasgow prognostic scores of 0 and 1/2, respectively. The median durations of progression-free and overall survival of the participants were 2.3 and 5.7 months, respectively. The patients with a Glasgow prognostic score of 0 had significantly higher median overall survival than those with scores of 1 or 2 (16.4 vs. 4.2 months; p = 0.0006). This observation suggests that a pretreatment Glasgow prognostic score of 0 is associated with better outcomes, and this scoring system may be used as a predictor of outcomes in patients with advanced gastric cancer treated with nivolumab.

scholarly journals Regional hyperthermia combined with chemotherapy in advanced gastric cancer

Open Medicine ◽  
2019 ◽  
Vol 14 (1) ◽  
pp. 85-90
Author(s):  
Hongming Fang ◽  
Yaping Zhang ◽  
Zhibing Wu ◽  
Xiaoyan Wang ◽  
Hui Wang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Prognostic Score ◽  
Glasgow Prognostic Score ◽  
Disease Stage ◽  
Regional Hyperthermia ◽  
Clinicopathologic Characteristics ◽  
Treatment Plans ◽  
Grade 3 ◽  
Clinical Potential

AbstractIntroductionThis study aims to investigate the potential effects of regional hyperthermia combined with chemotherapy (RHCT) as a treatment strategy for advanced gastric cancer (AGC).Method118 AGC patients were randomly divided into treatment plans with chemotherapy (CT) alone or with RHCT. The prognostic value of clinicopathologic characteristics was assessed in terms of overall survival of AGC patients.ResultsThe disease control rate was determined to be 70.9% and 46.0% for the RHCT and CT group, respectively (P = 0.006). The median survival was determined to be 23.5 months for the RHCT group and 14.0 months for the CT group (P = 0.010). The 3-year survival rate for the RHCT group was 11.4% and 0% for the CT group (P = 0.018). No difference in grade 3 or 4 adverse events was observed between the two groups (P > 0.05). Multivariate analysis showed that hyperthermia, disease stage, Glasgow prognostic score, and abdominal metastasis were closely associated with the prognosis of these AGC patients.ConclusionThe study suggests that combination treatment with RHCT for AGC has clinical potential for both short- and long-term curative effects without compromising toxicity.

The impact of modified Glasgow prognostic score on survival in patients with gastric cancer.

2013 ◽  
Vol 31 (4_suppl) ◽  
pp. 104-104
Author(s):  
Hironobu Goto ◽  
Masanori Tokunaga ◽  
Rie Makuuchi ◽  
Yutaka Tanizawa ◽  
Etsuro Bando ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Overall Survival ◽  
Serum Albumin ◽  
Serum Albumin Level ◽  
Prognostic Score ◽  
Glasgow Prognostic Score ◽  
Infectious Complications ◽  
Albumin Level ◽  
Modified Glasgow Prognostic Score ◽  
Serum Crp

104 Background: Modified Glasgow Prognostic Score (mGPS), based on serum C-reactive protein (CRP) and albumin-levels, was reported to be a good prognosticator for survival in patients with lung cancer. However, the role of mGPS in gastric cancer is still controversial. The aim of this study is to clarify the significance of mGPS as a prognosticator in patients with gastric cancer. Methods: This study included 1,062 patients who underwent gastrectomy for gastric cancer at Shizuoka Cancer Center between September 2002 and December 2006. Patients who received neoadjuvant chemotherapy, and those who had other cancers were excluded from the analysis. mGPS is defined by serum CRP level and serum albumin level. Patients with serum CRP level of 1.0mg/dl or lower were classified to mGPS 0 irrespective to the serum albumin level. Patients with elevated serum CRP level (>1.0mg/dl) were classified to mGPS1 or mGPS2 according to the serum albumin level (mGPS1, albumin≥3.5g/dl; mGPS2, albumin<3.5g/dl). We compared relationships between mGPS and clinicopathological characteristics of patients, the incidence of intra-abdominal infectious complications (Clavien-Dindo grade II or more severe), and overall survival. Results: There were 712 male and 350 female patients. The median age was 65 years old. The number of patients classified to the mGPS0, mGPS1, and mGPS2 group were 970 (91.3%), 59 (5.6%), and 33 (3.1%), respectively. The incidences of intra-abdominal infectious complications were 27.1% in mGPS1, and 24.3% in mGPS2, and were significantly higher than that in mGPS0 (9.5%, P< 0.001). Overall five-year survival rates were 74.6% in mGPS0, 61.4% in mGPS1, and 34.6% in mGPS2. The overall survival was significantly worse in patients with mGPS2 than those with mGPS0 or mGPS1 (P<0.001). Conclusions: mGPS was correlated with the incidence of intra-abdominal infectious complications. In addition, mGPS was found to be a prognosticator for survival in patients with gastric cancer. Preoperative nutritional support may lead to reduced incidence of surgical complications and improved survival outcome after gastrectomy in patients with gastric cancer.

scholarly journals A Survey of Attitudes towards the Clinical Application of Systemic Inflammation Based Prognostic Scores in Cancer

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
David G. Watt ◽  
Campbell S. Roxburgh ◽  
Mark White ◽  
Juen Zhik Chan ◽  
Paul G. Horgan ◽  
...  
Keyword(s):  
Systemic Inflammation ◽  
Clinical Guidelines ◽  
Online Survey ◽  
Prognostic Score ◽  
Glasgow Prognostic Score ◽  
Scoring Systems ◽  
Prognostic Scores ◽  
Patients With Cancer ◽  
Modified Glasgow Prognostic Score ◽  
The Glasgow Prognostic Score

Introduction.The systemic inflammatory response (SIR) plays a key role in determining nutritional status and survival of patients with cancer. A number of objective scoring systems have been shown to have prognostic value; however, their application in routine clinical practice is not clear. The aim of the present survey was to examine the range of opinions internationally on the routine use of these scoring systems.Methods.An online survey was distributed to a target group consisting of individuals worldwide who have reported an interest in systemic inflammation in patients with cancer.Results.Of those invited by the survey (n=238), 65% routinely measured the SIR, mainly for research and prognostication purposes and clinically for allocation of adjuvant therapy or palliative chemotherapy. 40% reported that they currently used the Glasgow Prognostic Score/modified Glasgow Prognostic Score (GPS/mGPS) and 81% reported that a measure of systemic inflammation should be incorporated into clinical guidelines, such as the definition of cachexia.Conclusions.The majority of respondents routinely measured the SIR in patients with cancer, mainly using the GPS/mGPS for research and prognostication purposes. The majority reported that a measure of the SIR should be adopted into clinical guidelines.

scholarly journals Glasgow Prognostic Score (GPS) and Tumor Response as Biomarkers of Nivolumab Monotherapy in Third- or Later-line Setting for Advanced Gastric Cancer

In Vivo ◽  
2020 ◽  
Vol 34 (4) ◽  
pp. 1921-1929
Author(s):  
TAKASHI KUROSAKI ◽  
HISATO KAWAKAMI ◽  
SEIICHIRO MITANI ◽  
RYOHEI KAWABATA ◽  
TAKAYUKI TAKAHAMA ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Tumor Response ◽  
Prognostic Score ◽  
Glasgow Prognostic Score ◽  
Line Setting
Sign in / Sign up

Export Citation Format

Share Document